GLP-1 Therapies & Adherence

For Innovators & Clinicians: While GLP-1 agonists represent one of the most significant therapeutic breakthroughs in decades, their commercial and clinical potential is capped by a critical, unmet challenge: long-term patient adherence. Studies show that up to 65% of patients discontinue their treatment within a year.